Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/50601| Conference/Presentation Title: | Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia. | Authors: | Chee L.C.Y.;Lee N.;Grigg A.;Chen M.;Schwarer A.;Szer J.;Yeung D.T.;Hughes T.;Shanmuganathan N. | Monash Health Department(s): | Haematology | Institution: | (Chee, Szer) Department of Medicine, The University of Melbourne, Parkville, Australia, Australia (Chee, Lee, Szer) Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia, Australia (Lee) Bendigo Cancer Centre, Bendigo Hospital, Bendigo, Australia, Australia (Grigg) Department of Clinical Haematology, Austin Health, Heidelberg, Australia, Australia (Chen) Monash Haematology, Monash Health, Clayton, Australia, Australia (Chen, Schwarer) Department of Haematology, Box Hill Hospital, Box Hill, Australia, Australia (Yeung, Hughes, Shanmuganathan) Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia, Australia (Yeung) Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia, Australia (Hughes) South Australian Health and Medical Research Institute SAHMRI, Adelaide, Australia, Australia (Shanmuganathan) School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia, Australia |
Presentation/Conference Date: | 23-Nov-2023 | Copyright year: | 2022 | Publisher: | Elsevier B.V. | Publication information: | Blood. Conference: 64th ASH Annual Meeting. New Orleans United States. 140(Supplement 1) (pp 6800-6802), 2022. Date of Publication: 15 Nov 2022. | Journal: | Blood | Abstract: | Background: Asciminib is the first tyrosine kinase inhibitor (TKI) to Specifically Target the ABL Myristoyl Pocket (STAMP). In the ASCEMBL Phase 3 randomised study comparing asciminib to bosutinib in patients with CML in chronic phase (CP) after 32 prior TKIs, asciminib demonstrated superior efficacy and tolerability vs bosutinib (major molecular response (MMR) rate at week 96: 37.6% vs 15.8%, treatment discontinuation 7.7% vs 26.3%) (Rea et al, EHA 2022). Here we present the real-world clinical outcomes of TKI-resistant/ intolerant CML patients in Australia who received asciminib through a MAP approved by Novartis. Method(s): All haematologists who had requested asciminib through MAP were approached to contribute data on the clinical outcomes of their CML patients. The database captured details on patient demographics, previous TKI use, reason for asciminib use (lack of efficacy vs intolerance), adverse events and efficacy based on BCR | Conference Name: | 64th ASH Annual Meeting | Conference Start Date: | 2022-12-10 | Conference End Date: | 2022-12-13 | Conference Location: | New Orleans, United States | DOI: | http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1182/blood-2022-163221 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/50601 | Type: | Conference Abstract | Subjects: | chronic myeloid leukemia | Type of Clinical Study or Trial: | Clinical trial |
| Appears in Collections: | Conference Abstracts |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.